DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Eribulin
Eribulin
Chemotherapeutic Agents for Brain Metastases in Non-Small Cell Lung
HALAVEN™ Safely and Effectively
BC Cancer Benefit Drug List September 2021
Insensitive Tumor Cells
Halaven® (Eribulin)
ERG Induces Taxane Resistance in Castration-Resistant Prostate Cancer
For Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline
Chemotherapy and Polyneuropathies Grisold W, Oberndorfer S Windebank AJ European Association of Neurooncology Magazine 2012; 2 (1) 25-36
Phase 1B Clinical Trial of Eribulin Mesylate and the PD-L1
Standard Oncology Criteria C16154-A
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts
Early Phase Clinical Studies Update
Cancer Drug Costs for a Month of Treatment at Initial Food
Eribulin As a First-Line Treatment for Soft Tissue Sarcoma Patients With
Assessment Report for Halaven Eribulin Procedure No. EMEA/H/C
Bc Cancer Chemotherapy Preparation and Stability
Top View
(Halaven) for Metastatic Breast Cancer
Pni/Jwci – Cipn
Halaven (Eribulin Mesylate)
2019 Table of Drugs
Table of Contents
Emerging Drugs for Prostate Cancer
Outpatient Cancer Drug Benefit Program List
Emetogenic Potential of Antineoplastic Agents
4CPS-079 Sequencing of Ibrutinib, Idelalisib and Venetoclax in Chronic
Open Full Page
Impressive Effect of Cisplatin Monotherapy on a Patient With
Indications Important Safety Information the First and Only Single
Broad-Spectrum Preclinical Antitumor Activity of Eribulin (Halaven®)
SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Photodynamic Therapy and Hyperthermia in Combination Treatment—Neglected Forces in the Fight Against Cancer
Eribulin in Cancer Treatment
Wear the Battle Gear That Protects Against 52 Chemotherapy Drugs!
HALAVEN, INN-Eribulin
Efficacy of Eribulin in Breast Cancer: a Short Report on the Emerging New Data
What About « Triple Negative » Breast Cancer
Arsenic Trioxide Inhibits Breast Cancer Cell Growth Via Microrna‑328/Herg Pathway in MCF‑7 Cells
Systemic Immunity Markers Associated with Lymphocytes Predict
Eribulin for Patients with Unresectable Or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen Christy L
Eribulin Inhibits Osteosarcoma in a Clinically-Accurate Bone-Tumor-Insertion PDOX Mouse Model NATHANIEL F
Phase II Trial of Eribulin Mesylate As a First- Or Second-Line
Overview of Cancer Therapy
Chemical Compatibility of Chemoclave™ and Chemolock™
Eribulin Mesylate (Halaven) When It Is Determined to Be Medically Necessary Because the Medical Criteria and Guidelines Shown Below Are Met
Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
[2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
Exploratory Biomarker Analysis from a Phase II Clinical Trial of Eribulin Plus
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
Full Prescribing Information for HALAVEN
HALAVEN, INN-Eribulin
PRIOR AUTHORIZATION CRITERIA MN-026 HALAVEN (Eribulin)
Table of Contents
Do Not Tube List
Chemotherapy Protocol BREAST CANCER ERIBULIN Regimen
All ETCTN Trials
Use of Closed Systems in the Hospital Pharmacy
BRE 186 Phase II Trial of Eribulin in Patients Who
Hazardous Drug List
Emetogenic Potential of Antineoplastic Agents
A Phase I Combination Dose-Escalation Study of Eribulin Mesylate and Gemcitabine in Patients with Advanced Solid Tumours: a Study of the Princess Margaret Consortium
SUMMARY REVIEW Office Director Review Page 1 of 6 NDA 201532 Halaven (Eribulin)
Breast Cancer
Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts Andrew J